Skip to main content

Table 3 Subgroup analysis

From: The efficacy and safety of thermal ablation for patients with lung malignancy: a meta-analysis of 12 studies in China

Subgroup

ORR

DCR

PFS

OS

No. of studies

OR and P

I2 (%)

No. of studies

OR and P

I2 (%)

No. of studies

HR and P

I2 (%)

No. of studies

HR and P

I2 (%)

Type of lung cancer

NSCLC

6

2.73; 0.003

60.5

5

2.44; 0.004

25.1

5

0.4; 0.001

78.7

3

0.57; 0.064

77.9

Lung cancer

2

2.95; 0.026

64.1

2

2.49; 0.001

0.0

2

0.48; 0.001

0.0

2

0.47; 0.001

0.0

Metastases

0

NA

NA

0

NA

NA

0

NA

NA

1

0.27; 0.001

0.0

Stage of lung cancer

Advanced

6

3.21; 0.001

65.4

5

2.54; 0.004

29.1

6

0.4; 0.001

73.8

4

0.55; 0.009

67.0

Other

2

2.05; 0.001

0.0

2

2.43; 0.001

0.0

1

0.5; 0.001

0.0

2

0.4; 0.001

42.8

Previous treatment naive?

Yes

4

2.51; 0.005

39.7

3

2.38; 0.027

45.0

5

0.4; 0.001

78.7

4

0.49; 0.008

74.4

No

1

1.22; 0.653

0.0

1

1.37; 0.693

0.0

0

NA

NA

0

NA

NA

NA

3

4.33; 0.005

73.7

3

2.7; 0.001

0.0

2

0.48; 0.001

0.0

2

0.47; 0.001

0.0

Randomized?

Yes

5

3.29; 0.001

56.9

4

3.31; 0.001

0.0

2

0.43; 0.001

0.0

1

0.38; 0.001

0.0

No

3

2.19; 0.028

58.1

3

2.05; 0.006

16.3

5

0.41; 0.001

79.2

5

0.52; 0.001

56.2

Type of ablation

RFA

4

2.11; 0.045

68.1

4

1.96; 0.008

9.6

2

0.65; 0.166

82.0

3

0.51; 0.017

77.8

MWA

4

3.76; 0.000

0.0

3

3.61; 0.001

0.0

5

0.34; 0.001

40.1

3

0.42; 0.001

0.0

Average age, year

 ≤ 60

5

2.81; 0.001

61.9

5

2.61; 0.001

0.0

4

0.45; 0.001

0.0

4

0.44; 0.001

0.0

 > 60

3

2.7; 0.034

59.6

2

2.2; 0.211

69.3

3

0.4; 0.086

88.0

2

0.51; 0.246

85.9

Average follow up, month

 > 24

2

2.98; 0.004

0.0

2

3.59; 0.001

0.0

4

0.51; 0.001

69.2

1

0.27; 0.001

0.0

 ≤ 24

2

1.75; 0.014

4.4

2

1.81; 0.048

25.6

0

NA

NA

4

0.53; 0.001

68.2

NA

4

3.91; 0.004

67.7

3

3.14; 0.007

0.0

3

0.29; 0.001

55.8

1

0.49; 0.029

0.0

HR extracted from KM curve?

Yes

NA

NA

NA

NA

NA

NA

4

0.51; 0.001

67.1

3

0.38; 0.001

0.0

No

NA

NA

NA

NA

NA

NA

3

0.31; 0.001

68.7

3

0.61; 0.031

65.3

  1. ORR objective response rate, DCR disease control rate, PFS progression-free survival, OS overall survival, OR odds ratio, HR hazard ratio, NSCLC non-small cell lung cancer, NA not available, RFA radiofrequency ablation, MWA microwave ablation